{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:22:57Z","timestamp":1771503777069,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["12X9420N"],"award-info":[{"award-number":["12X9420N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s13318-021-00698-w","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T15:04:27Z","timestamp":1627052667000},"page":"653-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct02365272","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5253-2960","authenticated-orcid":false,"given":"Sabrina","family":"De Winter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier","family":"van Hest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-7351","authenticated-orcid":false,"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"Meersseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nele","family":"Van den Eede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Desmet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Verelst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vanbrabant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willy","family":"Peetermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-0676","authenticated-orcid":false,"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"698_CR1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1097\/CCM.0b013e3181cc4824","volume":"38","author":"DF Gaieski","year":"2010","unstructured":"Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045\u201353.","journal-title":"Crit Care Med"},{"key":"698_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","volume":"39","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165\u2013228.","journal-title":"Intensive Care Med"},{"key":"698_CR3","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1093\/jac\/dkaa369","volume":"75","author":"M Elbaz","year":"2020","unstructured":"Elbaz M, Zadka H, Weiss-Meilik A, et al. Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. J Antimicrob Chemother. 2020;75:2307\u201313.","journal-title":"J Antimicrob Chemother"},{"key":"698_CR4","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1093\/jac\/dkaa348","volume":"75","author":"I Spriet","year":"2020","unstructured":"Spriet I, van Hest RM, Peetermans WE, et al. Comment on: Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. J Antimicrob Chemother. 2020;75:3696\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"698_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","volume":"38","author":"R G\u00e1lvez","year":"2011","unstructured":"G\u00e1lvez R, Luengo C, Cornejo R, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38:146\u201351.","journal-title":"Int J Antimicrob Agents"},{"key":"698_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","volume":"46","author":"C Roger","year":"2015","unstructured":"Roger C, Nucci B, Molinari N, et al. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents. 2015;46:21\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"698_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/jac\/27.suppl_C.91","volume":"27","author":"G Beaucaire","year":"1991","unstructured":"Beaucaire G, Leroy O, Beuscart C, et al. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother. 1991;27:91\u2013103.","journal-title":"J Antimicrob Chemother"},{"key":"698_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/0002-9343(84)90358-9","volume":"77","author":"RD Moore","year":"1984","unstructured":"Moore RD, Smith CR, Lietma PS. Association of aminoglycoside plasma level with therapeutic outcome in Gram-negative pneumonia. Am J Med. 1984;77:657\u201362.","journal-title":"Am J Med"},{"key":"698_CR9","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/cc8945","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Laterre PF, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14:R53.","journal-title":"Crit Care"},{"key":"698_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s00134-014-3276-x","volume":"40","author":"E de Montmollin","year":"2014","unstructured":"de Montmollin E, Bouadma L, Gault N, et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg\/kg total body weight regimen. Intensive Care Med. 2014;40:998\u20131005.","journal-title":"Intensive Care Med"},{"key":"698_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/FTD.0b013e31818b6b2f","volume":"30","author":"RS Rea","year":"2008","unstructured":"Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30:674\u201381.","journal-title":"Ther Drug Monit"},{"key":"698_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0310057X9302100206","volume":"21","author":"PE Marik","year":"1993","unstructured":"Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill patients. Anaesth Intensive Care. 1993;21:172\u20133.","journal-title":"Anaesth Intensive Care"},{"key":"698_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01706354","volume":"16","author":"C Triginer","year":"1990","unstructured":"Triginer C, Izquierdo I, Fern\u00e1ndez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 1990;16:303\u20136.","journal-title":"Intensive Care Med"},{"key":"698_CR14","first-page":"131","volume":"12","author":"EC Oparaoji","year":"1993","unstructured":"Oparaoji EC, Cornwell EE 3rd, Hekmat E, et al. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm. 1993;12:131\u20134.","journal-title":"Clin Pharm"},{"key":"698_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s00134-002-1313-7","volume":"28","author":"SE Buijk","year":"2002","unstructured":"Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002;28:936\u201342.","journal-title":"Intensive Care Med"},{"key":"698_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/00003246-199705000-00016","volume":"25","author":"G Lugo","year":"1997","unstructured":"Lugo G, Casta\u00f1eda-Hern\u00e1ndez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med. 1997;25:806\u201311.","journal-title":"Crit Care Med"},{"key":"698_CR17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1345\/aph.19104","volume":"34","author":"G Lugo-Goytia","year":"2000","unstructured":"Lugo-Goytia G, Casta\u00f1eda-Hern\u00e1ndez G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother. 2000;34:1389\u201394.","journal-title":"Ann Pharmacother"},{"key":"698_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1034\/j.1399-6576.1999.430707.x","volume":"43","author":"GJ Tang","year":"1999","unstructured":"Tang GJ, Tang JJ, Lin BS, et al. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand. 1999;43:726\u201330.","journal-title":"Acta Anaesthesiol Scand"},{"key":"698_CR19","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1128\/AAC.31.11.1855","volume":"31","author":"E Hassan","year":"1987","unstructured":"Hassan E, Ober JD. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Antimicrob Agents Chemother. 1987;31:1855\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"698_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/0310057X8801600406","volume":"16","author":"MJ Beckhouse","year":"1988","unstructured":"Beckhouse MJ, Whyte IM, Byth PL, et al. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care. 1988;16:418\u201322.","journal-title":"Anaesth Intensive Care"},{"key":"698_CR21","first-page":"5","volume":"8","author":"F Pea","year":"2013","unstructured":"Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol. 2013;8:5\u201312.","journal-title":"Curr Clin Pharmacol"},{"key":"698_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.emc.2019.04.002","volume":"37","author":"D Khoujah","year":"2019","unstructured":"Khoujah D, Martinelli AN, Winters ME. Resuscitating the critically ill geriatric emergency department patient. Emerg Med Clin North Am. 2019;37:569\u201381.","journal-title":"Emerg Med Clin North Am"},{"key":"698_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40262-016-0428-x","volume":"56","author":"A Marsot","year":"2017","unstructured":"Marsot A, Guilhaumou R, Riff C, et al. Amikacin in critically ill patients: a review of population pharmacokinetic studies. Clin Pharmacokinet. 2017;56:127\u201338.","journal-title":"Clin Pharmacokinet"},{"key":"698_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijantimicag.2017.11.009","volume":"51","author":"S De Winter","year":"2018","unstructured":"De Winter S, Wauters J, Meersseman W, et al. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and shock: a randomized controlled trial. Int J Antimicrob Agents. 2018;51:562\u201370.","journal-title":"Int J Antimicrob Agents"},{"key":"698_CR25","doi-asserted-by":"crossref","unstructured":"Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165\u2013228.","DOI":"10.1007\/s00134-012-2769-8"},{"key":"698_CR26","doi-asserted-by":"crossref","unstructured":"von Eckardstein A, Roth HJ, Jones G, et al. Cobas 8000 modular analyzer series evaluated under routine-like conditions at 14 sites in Australia, Europe, and the United States. J Lab Autom. 2013;18:306\u201327.","DOI":"10.1177\/2211068212472183"},{"key":"698_CR27","unstructured":"Beal S, Sheiner LB, Boekmann A, et al. NONMEM users guide. Ellicott City: Icon Development Solutions; 2011."},{"key":"698_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1365-2125.2006.02841.x","volume":"63","author":"RM van Hest","year":"2007","unstructured":"van Hest RM, van Gelder T, Bouw R, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63:741\u201352.","journal-title":"Br J Clin Pharmacol"},{"key":"698_CR29","unstructured":"Holford N. Poster 105: The visual predictive check\u2014superiority to standard diagnostic (Rorschach) plots. In: Abstracts of the Annual Meeting of the Population Approach Group in Europe, Pamplona, Spain. 2005. http:\/\/www.page-meeting.org\/page\/page2005\/Posters2005.pdf Accessed 25 Feb 2021."},{"key":"698_CR30","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters; v. 9.0, valid from 2019-01-01. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 25 Feb 2021."},{"key":"698_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/FTD.0b013e3181f675c2","volume":"32","author":"I Delattre","year":"2010","unstructured":"Delattre I, Musuamba FT, Nyberg J, et al. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit. 2010;32:749\u201356.","journal-title":"Ther Drug Monit"},{"key":"698_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijantimicag.2016.10.022","volume":"49","author":"CJ Hodiamont","year":"2017","unstructured":"Hodiamont CJ, Juffermans NP, Bouman CSC, et al. Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. Int J Antimicrob Agents. 2017;49:204\u201311.","journal-title":"Int J Antimicrob Agents"},{"key":"698_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00993-19","author":"C Boidin","year":"2019","unstructured":"Boidin C, Bourguignon L, Cohen S, et al. Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori pharmacokinetic\/pharmacodynamic target attainments in individual patients. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.00993-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"698_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13054-015-0741-z","volume":"19","author":"C Chelazzi","year":"2015","unstructured":"Chelazzi C, Villa G, Mancinelli P, et al. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015;19:26.","journal-title":"Crit Care"},{"key":"698_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00228-014-1766-y","volume":"71","author":"C Burdet","year":"2015","unstructured":"Burdet C, Pajot O, Couffignal C, et al. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol. 2015;71:75\u201383.","journal-title":"Eur J Clin Pharmacol"},{"key":"698_CR36","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41366-019-0476-z","volume":"44","author":"M L\u00f3pez-Mart\u00ednez","year":"2020","unstructured":"L\u00f3pez-Mart\u00ednez M, Luis-Lima S, Morales E, et al. The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors. Int J Obes (Lond). 2020;44:1129\u201340.","journal-title":"Int J Obes (Lond)"},{"key":"698_CR37","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00134-014-3376-7","volume":"40","author":"DK Matthaiou","year":"2014","unstructured":"Matthaiou DK, De Waele J, Dimopoulos G. What is new in the use of aminoglycosides in critically ill patients? Intensive Care Med. 2014;40:1553\u20135.","journal-title":"Intensive Care Med"},{"key":"698_CR38","doi-asserted-by":"publisher","first-page":"106124","DOI":"10.1016\/j.ijantimicag.2020.106124","volume":"56","author":"A Marsot","year":"2020","unstructured":"Marsot A, Hraiech S, Cassir N, et al. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens? Int J Antimicrob Agents. 2020;56:106124. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106124","journal-title":"Int J Antimicrob Agents"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00698-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T08:24:34Z","timestamp":1630052674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00698-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00698-w","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"20 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ED is a postdoctoral research fellow of the Research Foundation\u2014Flanders (FWO), Belgium (grant number 12X9420N). The other authors declare that no sources of funding were used to assist with the preparation of the results of this original research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"ED received consultancy fees from Argenx and Janssen (all honoraria\/fees were paid to the university). The other authors declare that there are no conflicts of interest that are relevant to the content of this original research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study received institutional approval from the Clinical Trial Center of University Hospitals Leuven (B32220109909).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirm that the data supporting the findings of this study are available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The authors confirm that the code is available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"SDW, RvH and IS designed the trial. ED, PA, JW, WM, SV, PV and WP participated in its design. SDW conducted the study and performed the database management. JW, WM, SV and PV participated in the recruitment of patients. NVdE and SD performed the laboratory analyses. RvH performed the population pharmacokinetic analysis. SDW and RvH performed statistical analyses. SDW, RvH, ED and IS drafted the article, and all authors participated in its critical revision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}